Biosafety in Microbiological and Biomedical Laboratories (BMBL)

Biosafety in Microbiological and Biomedical Laboratories (BMBL) is the United States’ primary reference for laboratory biosafety practice. It is produced jointly by the Centers for Disease Control and Prevention (CDC) and the National Institutes of Health (NIH), and is now in its 6th edition (2020). Because it is published under both agencies’ names and is often searched for as “NIH biosafety guidelines,” it is easy to confuse with the separate NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules — the two are related but distinct documents, covered below.

What BMBL Covers

BMBL defines the four-tier Biosafety Level (BSL) containment system — BSL-1, BSL-2, BSL-3, and BSL-4 — along with the standard and special microbiological practices, personal protective equipment, safety equipment (such as certified biosafety cabinets), and facility design and engineering controls required at each tier. It also provides agent summary statements for specific pathogens, describing their hazard characteristics, recommended precautions, and containment recommendations, and it sets out the risk-group classification system that informs (but does not mechanically dictate) the BSL assigned to a given protocol.

Advisory Reference, Not a Standalone Regulation

BMBL is explicitly written and understood as an advisory best-practice document — it is not itself a standalone federal regulation with independent enforcement authority. Its practical regulatory force comes from being incorporated by reference into frameworks that are binding: institutions covered by the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules must apply BMBL’s containment levels and practices when their Institutional Biosafety Committee (IBC) reviews and approves covered research, and institutions registered under the Federal Select Agent Program must meet BMBL-consistent containment requirements for the agents on the Select Agent List they hold. Outside those specific binding frameworks, an institution may not be legally compelled to follow BMBL, but it remains the de facto national standard that most research institutions, EHS offices, and IBCs adopt as their baseline regardless.

BMBL vs. the NIH Guidelines for Recombinant/Synthetic Nucleic Acid Molecules

These are two separate documents that are frequently searched for together, and both are commonly (if loosely) called “NIH biosafety guidelines”:

• BMBL is the CDC/NIH practices-and-containment-level reference — it answers “what physical practices, equipment, and facility controls does this level of risk require?”
• The NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules, issued by the NIH Office of Science Policy, is the binding compliance framework for institutions conducting or funded to conduct recombinant/synthetic nucleic acid research — it answers “who must review this work, under what governance structure, before it can start?” It requires a standing IBC and points to BMBL’s containment levels rather than redefining them.

In practice, the two work together: the NIH Guidelines set the governance and review requirements (IBC composition, registration, risk-category review), and BMBL supplies the technical containment-level content that governance process applies.

Who Uses BMBL

IBCs use BMBL’s agent summary statements and practice tables directly when reviewing and approving research protocols and assigning containment levels. Institutional EHS and biosafety offices build local laboratory biosafety manuals and standard operating procedures on top of BMBL’s framework, adapting its generic guidance to specific facilities, agents, and equipment. Biosafety officers reference it when training laboratory personnel and when investigating incidents or near-misses. Because Dual Use Research of Concern (DURC) policy also references BMBL-recommended BSL-3/BSL-4 handling as part of its Category 1 trigger criteria, biosafety and research-security offices frequently consult BMBL jointly.

Frequently Asked Questions

Is BMBL a law or regulation?

No. BMBL is an advisory best-practice reference. It becomes practically binding only through incorporation by reference into other frameworks that are themselves binding, such as the NIH Guidelines and the Federal Select Agent Program.

How often is BMBL updated?

BMBL has gone through multiple editions since it was first published in 1984; the current edition is the 6th (2020). Editions are not on a fixed annual cycle — institutions should confirm they are working from the current edition rather than assuming a set revision schedule.

Who publishes BMBL?

It is a joint publication of the CDC (Office of Health and Safety) and the NIH.

Does BMBL apply to every laboratory?

Not by direct legal mandate on its own. Laboratories conducting recombinant/synthetic nucleic acid research under the NIH Guidelines, or holding select agents under the Federal Select Agent Program, are effectively required to apply BMBL-consistent containment. Many other laboratories adopt it voluntarily as the recognized national baseline for biosafety practice.